The agreement includes significant milestone payments to Foamix upon the attainment of development, regulatory and clinical goals, with Foamix responsible for the foam formulation development of the products. Leo will be responsible for the clinical and regulatory development as well as sales and marketing of the products in the agreed territories.
Psoriasis is a skin disorder that most commonly appears as inflamed, edematous skin lesions covered with a silvery white scale. The most common type of psoriasis is plaque psoriasis. Nearly 13 million people worldwide suffer from psoriasis with more than 7 million people of these in the US.
“Leo Pharma’s products are currently the leading non-steroidal topical treatments for psoriasis, and we expect that our new foam formulations will expand our position in the dermatological arena,” said Ernst Lunding, President and CEO of Leo.